Early initiation of bronchodilators may prolong time to first exacerbation among COPD patients - Medical Dialogues

A new study published in BMC Journal of Respiratory Research shows that initiation of long-acting bronchodilators within 30 days of the diagnosis of chronic obstructive pulmonary disease (COPD) provided favorable outcomes..

It is uncertain if early therapy beginning with inhaled long-acting bronchodilators reduces exacerbations of chronic obstructive pulmonary disease better than delayed treatment commencement.

In order to determine if initiating long-acting bronchodilator medication within 30 days of a COPD diagnosis lowers the likelihood of exacerbations in COPD patients, Hideyasu Yamada undertook this study.

Patients were divided into two groups: "rapid therapy" patients who began inhaling long-acting bronchodilator medication within the first 30 days, and "delayed therapy" patients who did not.

The clinical results in individuals with CB or emphysema were favorably impacted by starting bronchodilator medication within 30 days of diagnosis.

Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort study.